Paul van der Valk

5.7k citations

118 papers · 3.6k indexed · h-index 34

Issues, ethics and legal aspects top 1%
Oncology top 2%
- Drug Transport and Resistance Mechanisms 9
- Viral-associated cancers and disorders 7
Pulmonary and Respiratory Medicine top 2%
- Chronic Obstructive Pulmonary Disease (COPD) Research 32
- Respiratory Support and Mechanisms 8
Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment 9
Cancer Research top 5%
Physiology
- Asthma and respiratory diseases 14
Hematology
- Hemophilia Treatment and Research 12
Epidemiology
- Chronic Disease Management Strategies 8

Co-authors: Job van der Palen Jan P. A. Baak Johannes S. de Jong Gerhard Zielhuis Cees van Herwaarden Evelyn M. Monninkhof P. J. van Diest Giuseppe Giaccone
Cited by: Issues, ethics and legal aspects Oncology Pulmonary and Respiratory Medicine
Journals: The Lancet (1 paper)The Journal of Experimental Medicine (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations: Netherlands Australia United States

In The Last Decade

Paul van der Valk

113 papers receiving 3.5k citations

Peers

Countries citing papers authored by Paul van der Valk

Since Specialization

Citations

This map shows the geographic impact of Paul van der Valk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul van der Valk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul van der Valk more than expected).

Fields of papers citing papers by Paul van der Valk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul van der Valk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul van der Valk. The network helps show where Paul van der Valk may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paul van der Valk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul van der Valk Line = papers co-authored together Paul van der Valk links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Clotting factor activity levels and bleeding risk in people with haemophilia playing sports Haemophilia ·Olav Versloot,Ellen Kemler,Johan Blokzijl,Merel A. Timmer,Marleen Schuuring,Karin P. M. van Galen,Idske C. L. Kremer Hovinga,Paul van der Valk,Lize F. D. van Vulpen,Roger E. G. Schutgens,Casper F. van Koppenhagen,Janjaap van der Net,Kathelijn Fischer	2023	5
2	Can motor proficiency testing predict sports injuries and sports‐induced bleeds in people with haemophilia? Haemophilia ·Olav Versloot,Johan Blokzijl,Merel A. Timmer,Marleen Schuuring,Karin P. M. van Galen,Idske Kremer Hovinga,Paul van der Valk,L. van Vulpen,Roger E. G. Schutgens,Casper van Koppenhagen,Janjaap van der Net,Kathelijn Fischer	2023	1
3	Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study Haemophilia ·Martijn R Brands,E Janssen,Marjon H. Cnossen,Cees Smit,Lize F. D. van Vulpen,Paul van der Valk,Jeroen Eikenboom,Floor Heubel-Moenen,Louise Hooimeijer,Paula F. Ypma,Laurens Nieuwenhuizen,Michiel Coppens,Saskia E.M. Schols,Britta A. P. Laros‐van Gorkom,Frank W.G. Leebeek,M.H.E. Driessens,Frits R. Rosendaal,Johanna G. van der Bom,Karin Fijnvandraat,Samantha C. Gouw	2023	0
4	New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia Thrombosis and Haemostasis ·Jan Astermark,Cihan Ay,Manuela Carvalho,Roseline d’Oiron,Philippe de Moerloose,Gerard Dolan,Pierre Fontana,Cédric Hermans,Pål André Holme,Όλγα Κατσαρού,Gili Kenet,Robert Klamroth,Maria Elisa Mancuso,Natascha Marquardt,Ramiro Núñez,Ingrid Pabinger,Robert C. Tait,Paul van der Valk	2021	0
5	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study Blood Advances ·Paul van der Valk,Michael Makris,Kathelijn Fischer,Robert C. Tait,Pratima Chowdary,Peter W. Collins,Karina Meijer,Lize F. D. van Vulpen,Eveline P. Mauser‐Bunschoten,Roger E. G. Schutgens	2021	18
6	Adherence to an eHealth Self-Management Intervention for Patients with Both COPD and Heart Failure: Results of a Pilot Study International Journal of COPD ·Joanne Sloots,Mirthe Bakker,Job van der Palen,Michiel Eijsvogel,Paul van der Valk,Gerard C.M. Linssen,Clara van Ommeren,Martijn Grinovero,Monique Tabak,Tanja Effing,Anke Lenferink	2021	17
7	Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc SHILAP Revista de lepidopterología ·Marissa J.M. Traets,Kathelijn Fischer,Nanda Uitslager,Paul van der Valk,Idske C. L. Kremer Hovinga,Lize F. D. van Vulpen,Roger E. G. Schutgens	2020	2
8	Patients with underuse or overuse of inhaled corticosteroids have different perceptions and beliefs regarding COPD and inhaled medication Patient Preference and Adherence ·Kirsten Koehorst-ter Huurne,Marjolein Brusse‐Keizer,Paul van der Valk,Kris L. L. Movig,Job van der Palen,Christina Bode	2018	6
9	Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD Respiratory Medicine ·Hendrik J. Prins,Ruud Duijkers,René Lutter,Johannes M. A. Daniels,Paul van der Valk,Margreet Schoorl,Huib A.M. Kerstjens,Tjip S. van der Werf,Wim Boersma	2017	36
10	Associations between comorbid load and baseline characteristics in COPD patients with comorbidities: Preliminary results European Respiratory Journal ·Anke Lenferink,Job van der Palen,Peter Frith,Paul van der Valk,Tanja Effing	2014	1
11	Comparing The Ease Of Use, Preference And Satisfaction Of Accuhaler/Diskus And Elpenhaler In Patients With Asthma Or Chronic Obstructive Pulmonary Disease American Journal of Respiratory and Critical Care Medicine ·Job van der Palen,Paul van der Valk,Martijn Goosens,Karin Groothuis‐Oudshoorn,Marjolein Brusse‐Keizer	2013	1
12	Preference, satisfaction and errors with two dry powder inhalers in patients with COPD Expert Opinion on Drug Delivery ·Job van der Palen,T Ginko,Axel Kroker,Paul van der Valk,Martijn Goosens,Laura Padullés,Beatriz Seoane,Ludmyla Rekeda,Esther García Gil	2013	58
13	Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier Journal of Neuroinflammation ·Ruben van Doorn,Melissa A Lopes Pinheiro,Gijs Kooij,Kim Lakeman,Bert van het Hof,Susanne MA van der Pol,Dirk Geerts,Jack van Horssen,Paul van der Valk,Elizabeth van der Kam,Eric Ronken,Arie Reijerkerk,Helga E. de Vries	2012	104
14	[Specialization versus generalization in pathology]. PubMed ·Paul van der Valk	2007	2
15	Effect of Discontinuation of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: The COPE Study American Journal of Respiratory and Critical Care Medicine ·Paul van der Valk,Evelyn M. Monninkhof,Job van der Palen,Gerhard Zielhuis,Cees van Herwaarden	2002	217
16	Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops The Journal of Pathology ·Johannes S. de Jong,P. J. van Diest,Paul van der Valk,Jan P. A. Baak	1998	145
17	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy International Journal of Cancer ·Sabine C. Linn,Herbert M. Pinedo,J van Ark-Otte,Paul van der Valk,Klaas Hoekman,Aafke H. Honkoop,Jan B. Vermorken,Giuseppe Giaccone	1997	7
18	Adenolymphoma and non-Hodgkin's lymphoma of the salivary glands and oral cavity in immunocompetent patients are not associated with latent Epstein-Barr virus Oral Oncology ·Eppo B. Wolvius,Natasha Jiwa,Paul van der Valk,A Horstman,I. van der Waal	1997	8
19	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy International Journal of Cancer ·Sabine C. Linn,Herbert M. Pinedo,J van Ark-Otte,Paul van der Valk,Klaas Hoekman,Aafke H. Honkoop,Jan B. Vermorken,Giuseppe Giaccone	1997	84
20	Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: A pilot study Biotherapy ·Johanna W. Baars,J. C. M. Fonk,R.J. Scheper,Bert Flier,Herman Bril,Paul van der Valk,Herbert M. Pinedo,John Wagstaff	1992	8

About Paul van der Valk

Paul van der Valk is a scholar working on Issues, ethics and legal aspects, Hematology and Pulmonary and Respiratory Medicine, having authored 118 papers that have together received 3.6k indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (32 papers), Asthma and respiratory diseases (14 papers), Hemophilia Treatment and Research (12 papers), Drug Transport and Resistance Mechanisms (9 papers), Lymphoma Diagnosis and Treatment (9 papers), Chronic Disease Management Strategies (8 papers), Respiratory Support and Mechanisms (8 papers) and Viral-associated cancers and disorders (7 papers). The work is most often cited by research in Issues, ethics and legal aspects (83 citations), Oncology (1.2k citations) and Pulmonary and Respiratory Medicine (1.1k citations). Paul van der Valk has collaborated with scholars based in Netherlands, Australia and United States. Frequent co-authors include Job van der Palen, Jan P. A. Baak, Johannes S. de Jong, Gerhard Zielhuis, Cees van Herwaarden, Evelyn M. Monninkhof, P. J. van Diest, Giuseppe Giaccone, Paul J. van Diest and Rik J. Scheper. Their work appears in journals such as The Lancet, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact